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Abstract: Hypersialylation of tumour cell surface proteins along with a marked up-regulation 
of sialyltransferase (ST) activity is a well-established hallmark of cancer. Due to the critical 
role of STs in tumour growth and progression, ST inhibition has emerged as a potential new 
antimetastatic strategy for a range of cancers including pancreatic and ovarian. Human STs 
are divided into subtypes based on their linkage and acceptor molecule, with each subtype 
controlling the synthesis of specific sialylated structures with unique biological roles. This has 
important implications for inhibitor development, as STs also play significant roles in immune 
responses, inflammation, viral infection and neurological disorders. Thus, the current goal in 
order to advance to the clinic is the development of subtype selective, cell-permeable and 
synthetically accessible, small-molecule ST inhibitors. Herein, is a comprehensive review of 
the latest developments in ST inhibitors from design, Nature and high-throughput screening, 
addressing both the challenges and opportunities in targeting cell surface sialylation. The 
review features an overview of the biological evaluation methods, computational and imaging 
tools, inhibitor molecular diversity and selectivity towards ST subtypes, along with the 
emerging role of ST inhibitors as diagnostic tools for disease imaging. 
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Sialic acid is the body's most important sugar next to glucose.1 Sialylation, the addition of 
sialic acid to cell surface molecules via sialyltransferase enzymes, is integral to cell function, 
governing numerous important biological processes including cell-cell recognition, adhesion, 
protein targeting and fertilization.2 However, aberrant sialylation is a hallmark of cancer, with 
hypersialylation of up to 30% seen in many cancers, along with marked up-regulation of 
sialyltransferase activity. This is directly correlated with increased metastatic potential and 
poor patient prognosis.3,4 Sialylation mediates tumour metastasis via several routes including 
stimulating tumour invasion and migration through integrin-mediated processes,5,6 promoting 
tumour survival by blocking galectin binding,7 and inhibiting Fas-mediated apoptosis.4,8 Due 
to the critical role of sialyltransferases (STs) in tumour metastasis, ST inhibition has emerged 
as a potential new anti-metastatic treatment for several cancers.9 
There are 20 human STs divided into four groups based on their linkage type and acceptor 
molecule: ST3Gal I-VI; ST6Gal I-II; ST6GalNAc I-VI; and ST8Sia I-VI.10 Each ST controls 
the synthesis of specific sialylated structures with unique biological roles, such as Lewis 
antigen sialylation by ST3Gal III, IV and VI and β1 integrin sialylation by ST6Gal I.11 Thus, 
it is critical for the advancement of this field that selective inhibitors are used to unravel the 
roles of individual STs in tumour growth, metastasis and disease progression and for the 
development of a new treatment strategy for a range of treatment resistant cancers including 
pancreatic and ovarian cancer. Furthermore, resistance to frontline therapies such as paclitaxel 
and the platinum-based drugs cisplatin and carboplatin, is a critical issue in cancer treatment 
resulting in significant disease relapse, and reducing patient survival rates. Upregulation of 
STs has been shown to produce cellular resistance in both paclitaxel and cisplatin treatment in 
human ovarian and colorectal cancer cell lines along with reducing treatment efficacy.12   This 
demonstrates that small molecule inhibitors of STs could be used either alone as a new 
therapeutic treatment for selected cancers, or in combination with existing drugs to enhance 
their sensitivity in resistant tumours.  
Herein, we review the latest achievements in the development of ST inhibitors by design, 
from Nature and from high-throughput screening (HTS), along with examining the emerging 





A. Sialic Acid 
Sialic acids belong to a family of sugars containing a nine-carbon backbone bearing a carboxy 
group at the 1-position, a hydroxy group at the 2-position and an amino group at the 5-
position, with over 50 derivatives known.1,13 N-Acetylneuraminic acid, Neu5Ac (1) is the 
most ubiquitous and well known member of this family alongside other important members 
including the 5-glycolylamido derivative Neu5Gc (2) and the non-aminated derivative 2-keto-
3-deoxynononic acid, KDN (3) (Fig. 1).2,14 Higher animals and some microorganisms 
biosynthesize sialic acids from ManNAc for use in many reactions. Ubiquitous components of 
mammalian glycoproteins and glycolipids, they are a family of closely related neuraminic 
acids found at the non-reducing terminal positions of glycoconjugates, usually attached to the 
exposed terminus of N- and O-linked glycans of glycoproteins. Sialic acid thus represents one 
of the most important constituents of glycoconjugates in biological systems.1,2,14 
 
Figure 1. Structures of selected sialic acids. 
Due to their terminal position and their negative charge at physiological pH, sialylated 
oligosaccharide sequences are key information containing molecules and critical determinants 
in cell-cell recognition processes, cell-matrix interactions and maintenance of serum 
glycoproteins in the circulation.15,16 The cell surface sialic acid residues have been known to 
act as receptors for the influenza virus.17 They are often function in the “anti-recognition” or 
masking of the carbohydrate groups they terminate.16 The highest concentration of sialic acid 
(as Neu5Ac) in the human body occurs in the brain where it is an integral part of ganglioside 
structure. Consistent with this finding, human milk contains a high concentration of sialic 
acid, which is associated with the increase of gangliosides in the brain and is potentially 
linked to improved learning ability.18 
 
Wang and Brand-Miller have reviewed the role of sialic 
acid in human nutrition and the link between sialic acids, breastfeeding and learning 
behaviour.19 Conversely, a reduction in sialic acid is correlated with erythrocyte destruction.20 
B. Sialyltransferases 
Sialyltransferases are a subset of glycosyltransferases (GTs) involved in the biosynthesis of 
sialylated glycolipids and/or glycoproteins. Sialyltransferases catalyse the addition of sialic 
acid residues from the β-glycoside donor cytidine monophosphate N-acetylneuraminic acid, 
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CMP-Neu5Ac (4) (Fig. 2) to the terminal position of growing oligosaccharide chains of 
glycoconjugate acceptors, to produce α-sialosides. In vertebrates, CMP-Neu5Ac is produced 
in the cell nuclei and transported to the Golgi apparatus where sialylation takes place.21-23 
Depending on the glycosidic linkage formed and their glycoconjugate acceptor, vertebrate 
STs are arranged into four families (ST3Gal, ST6Gal, ST6GalNAc and ST8Sia; Table I). STs 
families are further subdivided into 20 sub-types in mammals that are highly conserved from 
mouse to man24 and more than 25 sub-types in lower vertebrates, each of them being 
characterized by conserved amino acid positions. All utilise CMP-Neu5Ac as the activated 
sugar donor to catalyse the transfer of sialic acid residues to terminal non-reducing positions 
of oligosaccharide chains of glycoproteins and glycolipids.25,26 
 
Figure 2. Mechanism of the sialylation reaction and expected products by sialyltransferase subtypes. 
STs differ in their substrate specificity, tissue distribution and various biochemical 
parameters. Enzymatic analysis conducted in vitro with recombinant enzyme revealed 
that one linkage can be synthesised by multiple enzymes.27,28 Moreover, even though 
eukaryotic STs share the same sugar donors, i.e. CMP-Neu5Ac (4), and recognize identical 
acceptor substrates, they do not exhibit similar protein structure except for the four short and 
conserved consensus sequences present in the catalytic domain.29,30 STs have been shown to 
be primarily topologically restricted to trans cisternae and the trans Golgi network of the  
6 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































a HGNC: Hugo Gene Community Nomenclature 
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Golgi apparatus, although catalytically active soluble forms can be generated in vivo by 
proteolytic cleavage at the stem region, e.g. serum soluble ST6Gal I.31 The existence of cell 
surface ST activity has also been reported for human monocyte-derived dendritic cells.32 Due 
to the paucity of efficient selective, cell permeable inhibitors, much of the available 
information regarding the importance of sialyltransferases has come from gene ablation in 
mice.33,34 Recent research has led to further understanding of the biological involvement of 
these enzymes in a host of disease states, further extending the array of potential therapeutic 
applications of this target.35,36 
C. Sialylation in Cancer 
Elevated plasma levels of STs have been observed in cancer patients since the 70's, and 
hypersialylation of cell surface proteins is now a well-established hallmark of cancer that 
forms the basis of several diagnostic cancer markers.40-42 One such example is the 
carbohydrate antigen CA19-9 for pancreatic cancer, which results from overexpression of 
ST3Gal III, IV and VI leading to the production of large amounts of sialyl Lewisa (sLea). 
Sialylated glycans have long been predicted as cell-type specific markers and critical 
determinants in various cellular recognition processes (cell–cell recognition, adhesion, protein 
targeting, blood coagulation, fertilization, and other biological events).43 They also play 
significant roles in immune responses,44 inflammatory diseases, viral infection45,46 and tumour 
proliferation,47 migration, and metastasis.48-50 STs have been described as “engines of self-
fuelling loops in cancer progression”.4,8,51 Hypersialylated integrins are believed to facilitate 
cell migration in many different cancer types,52 such as colon,53,54 lung55,56 and ovarian 
cancer.11 Aberrant sialylation at the non-reducing end of glycoproteins or glycolipids has been 
shown to promote events involving abnormal stimuli in the interaction of neoplastic cells with 
extracellular matrices.9 The biosynthesis of sialylated glycoprotein, mediated by ST6GalNAc 
IV, was also reported on various kidney cancer cell lines.57 Before considering membrane 
sialylated glycoproteins as a target for treating cancer, these molecular patterns are useful in 
the prognosis of cancer58,59 and other diseases.60 Tumour cell migration and invasion are 
regulated by sialylated glycoforms of integrins. Specifically, β1 in colon 
adrenocarcinomas53,54 and lung,55,56 where ST expression, in particular ST6Gal I,61 ST3Gal 
I,62,63 ST3Gal III,48,61 ST3Gal IV,48,64 ST6GalNAc I65 and ST6GalNAc V66 are strongly 
correlated with tumour invasiveness. This is also the case in numerous other cancers 
including, bladder,63 breast,67 pancreatic,68 ovarian,11 gastro-intestinal69 cancers and 
leukemia.70 (Fig. 3). 
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Lung Cancer: Sialyl Lewis x (SLex) is a well-known tumour-associated antigen that is 
found in elevated levels in lung cancer. It facilitates cell adhesion to the endothelium, 
initiating the process of extravasation and metastasis. ST3Gal III, IV and VI enzymes play a 
key role in the synthesis of SLex. In lung cancer, expression levels of both SLex and ST3Gal 
III are inversely correlated with patient survival.71 Hypersialylation and increased expression 
of SLex is also observed in the mucins of cystic fibrosis patients,72 while over-sialylation of 
several other proteins including integrins has also been shown to enhance cell invasion in 
ovarian, colon and lung cancer. ST3Gal I is not detected in normal human bronchial epithelial 
cells, but is over-expressed in highly metastatic lung cancer cells such as A549 and CL1-5.56 
Thus, inhibition of STs, in particular the ST3Gal subfamily, has emerged as a new target for 
the treatment of early lung cancer, and to aid in understanding the progression to more 
aggressive phenotypes. 
Ovarian Cancer: Increased serum glycoprotein sialylation in a murine ovarian carcinoma 
model has been found to correlate with inflammation and tumour progression, with increased 
expression of ST3Gal I and ST6Gal I.73 The latter also regulates ovarian tumour cell survival 
mechanisms74 and confers cisplatin resistance.75,76 CA125, the clinically used ovarian cancer 
marker is a heavily glycosylated mucin (MUC16).62 Levels of sialyl-Tn antigen, expressed on 
MUC16 in patients, is found to differ between endometriosis and ovarian cancer raising the 
potential for its use in diagnosis, and evaluating the clinical stage, cytological grade, and 
histological type of ovarian cancer.77 
Breast Cancer: STs have been found to play a key role in breast cancer progression, 
aggressiveness, metastasis and drug resistance. Recent studies in triple-negative breast cancer 
patient-derived xenograft models treated with standard chemotherapy identified high levels of 
the sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4). This treatment-resistant 
breast cancer subpopulation also exhibited high expression of ST3Gal II, which is required for 
the biosynthesis of SSEA4. This could be used as a potential predictive biomarker of poor 
clinical outcomes in both breast and ovarian cancer patients treated with standard-care 
genotoxic chemotherapy.78 Gene expression analysis coupled with functional analysis of 
clinical samples has also identified ST6GalNAc V as a key mediator of breast cancer 
metastasis to the brain. Atypical expression of this brain ST in breast cancer cells is thought to 
facilitate their passage through the blood-brain barrier.79  
The transmembrane tumour-associated glycoprotein Mucin 1 (MUC1) is aberrantly 
glycosylated and overexpressed in a variety of epithelial cancers, where it is involved in 
intracellular signal transduction pathways.80 A strong correlation between the expression of 
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MUC1 and T antigen has been found in breast cancer tumours and breast cancer cell lines, 
along with the down-regulation of expression of core 2 β-1,6-N-
acetylglucosaminyltransferase (C2GnT1) and ST3Gal I.81 Cyclooxygenase-2 (COX-2) is 
involved in the upregulation of ST3Gal I in MDA-MB-231 breast cancer cell lines leading to 
increased sialylation of the ST3Gal I substrate, core 1 Gal-β-1,3-GalNAc, which can be 
reversed using the COX-2 inhibitor celecoxib. Expression analysis of 74 primary breast 
cancers showed a significant correlation between ST3Gal I and COX-2, indicating that 
malignant characteristics of COX-2 expression may be related to tumour cell surface 
sialylation.82 On a different note, cationic amphibian antibacterial peptides such as aurein 1.2 
from the glands of the Litoria sp. frog and buforin IIb derived from the Asian toad Bufo 
garagriozans, exploit the upregulation of sialylation in breast cancer cells (MX-1 and MCF-7) 
to enhance their binding to sialylated N-, O-glycoproteins and gangliosides on the tumour cell 
surface. This may contribute to their selective cancer toxicity. Buforin IIb also supressed 
tumour growth in a MX-1 xenograft mouse model via induction of apoptosis and inhibition of 
vascularization.83 
Multiple Myeloma: High expression of ST3Gal VI has been identified in patients with 
multiple myeloma (MM) and correlated to poor patient prognosis. Knockdown of ST3Gal VI 
in MM cell lines MM1S and RPMI-8226 significantly reduced α-2,3-linked sialic acids on the 
cell surface and reduced adhesion to bone marrow stromal cells and fibronectin. It further 
inhibited transendothelial migration in vitro and reduced homing and engraftment, decreased 
tumour burden and increased survival in vivo in a xenograft (SCID-Bg) mouse model.84 
Leukemia and Glioma: Elevated mRNA levels of ST expression have been found to 
positively correlate with a high risk of numerous cancers including paediatric leukemia, where 
it has been suggested as a potential biomarker.85 In particular, cell surface sialylation is 
emerging as an important feature of cancer cell multidrug resistance (MDR). Recently, the α-
2,8-sialyltransferases ST8Sia IV and ST8Sia VI were found to positively correlate with the 
multidrug resistant phenotype in chronic myeloid leukemia (CML) cells, with ST8Sia IV 
appearing to regulate the activity of PI3K/Akt signalling and P-gp expression.86,87 
Overexpression of ST6GalNAcV, a ganglioside-specific α2,6-sialyltransferase, inhibits 
glioma growth in vivo.88 
Metastasis and MDR: Also of important consideration is metastasis, a major challenge in 
the treatment of cancer, largely responsible for the high rate of cancer mortality. It is 
emerging that molecules conferring drug resistance may also promote metastatic invasion. 
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developing inhibitors that are selective for particular ST-subtypes, along with exploration of 
targeted delivery of ST inhibitors directly to the tumour site. 
E. Immune System, Inflammation and Others 
Not only are STs an attractive target for cancer, they also present interesting applications in 
other biological fields. The ST6Gal I sialyltransferase controls production of the Sia-α-2,6-
Gal-β-1,4-GlcNAc (Sia6LacNAc) trisaccharide, which is the ligand for the lectin CD22. 
Binding of CD22 to Sia6LacNAc is implicated in regulating lymphocyte adhesion and 
activation. Knock-out ST6Gal I mice were found to be viable and thus constitute a good 
model for immunodepression, unlike CD22-deficient mice. Human sialoconjugates 
incorporate the Neu5Ac form of Sia in constrast to Neu5Gc in mice, which is the main 
difference.114 Notably, Sia6LacNAc-deficient mice displayed reduced serum IgM levels, 
impaired B cell proliferation in response to IgM and CD40 crosslinking, and attenuated 
antibody production to T-independent and T-dependent antigens. Deficiency of ST6Gal was 
further found to alter phosphotyrosine accumulation during signal transduction from the B 
lymphocyte antigen receptor. These studies reveal that the ST6Gal I sialyltransferase and 
corresponding production of the Sia6LacNAc oligosaccharide are essential in promoting B 
lymphocyte activation and immune function.34 Other disease states linked to a loss of ST gene 
function include allergies, where deficiencies in ST6Gal I and ST3Gal III production in mice 
is associated with enhanced allergic airway inflammation.115,116 
Leukocytes are activated by binding to α-2,3-sialylated glycans and as a result, promotes 
immunodepression due to a deficiency in the ST3Gal IV and VI enzymes.117 Leukocyte 
accumulation was also shown to play a key role in atherosclerosis. In this field, ST3Gal-IV 
has been identified as a promising target to reduce inflammatory leukocyte recruitment. 
Studies by Doering et al. have shown ST3Gal-IV deficiency leads to reduced chemokine Ccl5 
binding and Ccl5-induced flow arrest of myeloid cells, with marked reduction in the 
inflammatory cell content of lesions in a mouse model of atherosclerosis.118 Rifat et al. also 
investigated the influence of α-2,6-sialylated glycans on modulating the immunological 
characteristics of neutrophil granulocytes.119 
It has recently been shown that the immune killer cells’ activating receptors (NKG2D and 
CD94) bind to α-2,3-sialylated, but not to α-2,6-sialylated N-glycans.120 Reduction in 
cytotoxic T cells (CD8+) had been previously observed in mice after ablation of the ST3Gal I 
gene. Sialylation clearly plays a key role in the immune system121 and thus ST inhibition is 
also a promising therapeutic strategy against inflammation.122 
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As avian influenza viruses preferentially use α-2,3-linked sialic acid as a receptor for 
binding and entry into target cells, the selective inhibition of ST3Gal IV represents a potential 
target for antiviral drug design.123 Another study identified the implication of ST6Gal I in the 
infection of epithelial cells by  viruses pdmH1N1 and H3N2.45 The myxoma virus was 
previously shown to express α-2,3-STs and the resulting sialylated glycans promote 
infection.124 Cells infected with HIV were found to contain higher levels of STs than healthy 
cells.125 Sialylated glycoconjugates also constitute an important platform for host cell invasion 
for parasites, such as infection with Toxoplasma parasites.126 The Gram-negative bacteria 
Neisseria gonorrhoeae expresses an α-2,3-sialyltransferase (Lst) that scavenges sialic acid 
from the host and uses it to sialylate the terminal lacto-N-neotetraose moiety of its 
lipooligosaccharide (LOS). The resulting LOS sialylation is linked to serum resistance, 
decreased antibody binding and decreased effectiveness of antimicrobial peptides, and thus 
represents a potential new target for gonorrhea.127 
ST6Gal I128,129 and ST8Sia I130 are both downregulated in the liver by chronic alcohol 
consumption, along with reduced sialylation of serum transferrin and apolipoprotein E 
(apoE).131 This affects its ability to bind to high density lipoprotein (HDL) leading to impaired 
reversed cholesterol transport in alcoholics.132 In utero alcohol exposure is also found to alter 
the expression and sialylation of NCAM isoforms during brain development in rats.133 
Considerable alteration of ST8Sia II was observed in patients who received gastric 
bypass surgery.134 GWAS was conducted on 693 participants and showed reduced expression 
of the gene in ther liver and epididymal fat and revealed a significant association of the 
ST8Sia II gene expression with weight loss. 
The altered ST expression in a wide range of diseases highlights the critical and specific 
role that different ST subtypes play in human biology. Furthermore, it illustrates the growing 
need to develop selective inhibitors in order to further explore the intricate role of sialylation 
in human disease. 
F. Reviews 
The design and development of potent small molecule ST inhibition was pioneered by 
R.R. Schmidt and co-workers,135-138 almost two decades ago. The synthesis and biological 
evaluation of ST inhibitors appearing at that time have been reviewed previously and 
focussed on α-2,3-ST and α-2,6-ST subtypes.139-142 In the intervening years since the first 
development of ST inhibitors, a rising number of biological and medical-related papers 
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have appeared. This has expanded our understanding of the role of glycosylation in 
various disorders, as well as the role of altered sialylation in disease, in particular cancer 
and metastasis.143 For further reading in this area, there are several comprehensive reviews 
on the biological function of sialic acids by Schauer & Kelm,16,144,145 Varki1,2,36,146 and 
Crocker,147,148 and on the biological role of sialylation including reviews by Dall’Olio et 
al.,3,51,149 Schultz et al.,8 Harduin-Lepers et al.,26-28 and Boons et al.150 
Over the last decade, the therapeutic potential of targeting STs has appeared in part in 
reviews focusing on GTs and altered glycosylation in cancer from Brooks et al.,151,152 
Brown et al.,153 Compain & Partin,154 Gloster & Vocadlo,155 Hinou & Nishimura,156 Izumi 
et al.,157 Kajimoto & Node,158 Roychoudhury & Pohl,159 Schnaar et al.160 and Zhou et 
al.161 The last comprehensive small molecules review of ST inhibitors appeared over a 
decade ago, before the first ST crystal structures were reported.139,140 In recent years, 
along with the mounting evidence of the critical role of sialylation in cancer and growing 
structural information on STs, several new potent ST inhibitors have been described. 
These have been derived from various scaffolds and thus increasing the molecular 
diversity of ST inhibitors in the literature. Herein, we review the latest highlights in the 
design, development, biological evaluation and applications of ST inhibitors in both 
medicinal chemistry and as important tools in chemical biology. This review draws on the 
recent structural information available for STs, with a particular emphasis on the 
challenges in the field, such as selectivity of inhibitors toward the different ST subtypes, 
cell permeability, synthetic practicality, structure-based design and the emerging picture 
of structure-activity relationships. 
2. BIOLOGICAL ASSAYS 
A. Enzyme Assays 
A key challenge in the ST inhibitor field is the choice of biological assay employed to 
evaluate the effectiveness of newly developed inhibitors. There are no commercially 
available ST inhibitor screening assays at the time of writing, and very few commercial 
sources of mammalian ST enzymes, those being rST3Gal I (EC 2.4.99.4) from Merck 
(#566227) and hST6Gal I (EC 2.4.99.1) from Merck (#566223) and Roche (#07-012-250-
103). For this reason, most research groups clone, express and/or isolate their own ST 
enzymes, which are used in either crude, partially purified or purified form.27,162-170 As 
with all enzyme work, there are a wide range of enzymes used (e.g. predominantly human, 
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rat, and bacterial STs) and a variety of assays employed (colorimetric, fluorescent, 
radioactive, mass spectrometry and HPLC-based) to evaluate inhibitory activity, and this 
should be considered when comparing biological results. Herein, a brief description of the 
bioassays employed in the evaluation of ST inhibitors is included below, and in later 
sections the assay utilised by each research group is highlighted for each study. 
HPLC-based Assays: Earlier studies into sialyltransferases used asialofetuin or lacto-
N-tetraose as the acceptor moiety and 14C or 3H-labelled CMP-Neu5Ac171 as the donor 
and the radioactive products were isolated by chromatography or precipitation.171-173 In 
1998, RR Schmidt and co-workers introduced a HPLC-based assay using the p-
nitrophenyl glycoside of N-acetyllactosamine as a UV labelled acceptor, and this 
continues to be one of the most widely used ST inhibition assays today.135 Recent 
extensions of this method, include a continuous all-in-one HPLC-based assay that enables 
the quantification of productive turnover, error hydrolysis and site selectivity of 
sialyltransfer and donor substrate hydrolysis, with the potential for high-throughput 
screening.174 Further HPLC-based assays include those reported by Kijahara et al. and 
involve a combination of HPLC analysis with a fluorescent analytical technique based on 
reacting sialic acid with 1,2-diamino-4,5-methylenedioxybenzene,175 or using 2-[(2-
pyridyl)aminoethyl-β-D-lactosamidine as a ST acceptor for potential use in fluorescent 
assays.176 
Fluorescence-based Assays: Rillahan et al. designed a fluorescence polarisation (FP) 
assay enabling high-throughput screening of sialyl- and fucosyltransferases.177 The 
methods employs a CMP-Neu5Ac derivative bearing a fluorescein isothiocyanate (FITC) 
tag at the 9-position178 and asialofetuin as the acceptor. This technique has the advantage 
of being applicable for various enzyme subtypes by using a versatile acceptor, however, it 
does require the non-trivial preparation of the FITC-labelled CMP-Neu5Ac donor. 
Kumagai et al. have reported a multi-enzyme system allowing the screening of potential 
inhibitors against a wide variety of glycosyltransferases including glucosyl-, galactosyl-, 
glucuronyl-, xylosyl-, fucosyl- and sialyltransferases.179 Three kinase enzymes are used in 
order to provide glucose-6-phosphate (G6P) starting from the nucleoside monophosphate 
resulting from the glycosylation reaction. G6P dehydrogenase converts then resazurin, in a 
dose-dependant manner, to resorufin and the fluorescence of the solution is measured. 
This method presents the advantage of allowing HTS of compound libraries. 
MS-based Assays: Hosoguchi et al. designed a MS-based protocol suitable for HTS 
of potential GT inhibitors. The authors monitored the inhibition rate by looking at the 
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amount of glycosylated acceptor using MALDI-TOFMS.180 More recently, Preidl et al. 
designed a binding affinity assay in which the dissociation constant was determined by 
comparing the anisotropy changes in fluorescence polarisation.181 An alternative 
technique consists in immobilising the acceptor sugar on a plate or a cellulose membrane. 
This method was described using N-acetyllactosamine182 or trisialyl lactoside (GT3) by 
click-chemistry.183 Other assays using multi-enzyme systems combined with 
spectrophotometry53,184 or colorimetry185 have also been reported. 
B. Cell-based Assays 
Altered sialylation of the cell surface as a result of ST inhibition is expected to affect 
metastatic cell behaviours such as invasion, adhesion and migration, rather than cell viability. 
For this reason, classic cytotoxicity tests such as MTT and MTS assays have shown very little 
to no toxicity for a range of ST inhibitors, which greatly enhances their drug development 
potential.56,186-188 Thus, the most prevalent assays in this area are those that measure cell 
invasion;189 cell migration using Transwell chamber migration assays;55,186 cell adhesion to 
plates coated in collagen IV, fibronectin or laminin,55,56,189,190 along with traditional wound 
healing assays.55,186,191 Further anti-metastasis assays include those that assess activation of 
integrins and downstream mediators of integrin signalling, such as FAK (focal adhesion 
kinase),56,186 and PI3K/Akt signalling via Western blot analysis.
87 Other assays looking at the 
functional consequences of altered cell surface sialylation include examining effects on 
selectin-mediated leukocyte rolling in HL-60 cells and MS analysis of the N-glycans from 
inhibitor-treated cells as described by Rillahan et al,187 as well as effects on NCAM 
polysialylation via ST8Sia inhibition.188,192 Table II shows some of the cancer cell lines used 
in cell-based evaluation of ST inhibition. 
Other cell-based methods of determining the extent of ST inhibition include flow cytometry 
analysis of cell surface sialylation using biotinylated lectins. For example M. amurensis lectin 
II, which is specific for α-2,3-linked sialic acid and Sambucus nigra lectin, which is specific 
for α-2,6-linked sialic acid.55,56,181,187,189  
Lectin affinity has also been used to precipitate lectin/sialylated protein complexes out of cell 
lysates, followed by cleavage of the complex and Western blot analysis of the sialylated 
proteins.55,56 Cellular uptake of labelled ST inhibitors has been investigated using a range of 
cell staining techniques and confocal microscopy, successfully demonstrating the cell 
permeability of a range of ST inhibitors.56,181 
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Table II. Ccell lines used in sialyltransferase inhibition studies. 
Cancer type ST type Cell line Analysis Reference 
Breast cancer ST3/6Gal I MCF-7 
MDA-MB-231 
Viability, adhesion, migration, 
invasion, flow cytometry, lectin 
affinity, FAK 
Chang, 2011185





indirect NL-17 Cell attachment, cell-induced platelet 
aggregation 
Kijima-Suda, 1988189
 ST8Sia II & IV HL-60 Immunoblotting, quantitative RT-
PCR 
Horstkorte, 2004191





HL-60, Ramos cells Flow cytometry, glycan profiling, 
lectin affinity, leukocyte rolling 
assays 
Rillahan, 2012186
Lung cancer ST3/6Gal I CL1-0, CL1-5, CL1-
5F4, A549, H1299, 
BES-6b 
Viability, adhesion, migration, flow 




Melanoma ST3Gal I B16F10 (murine) Adhesion, migration, invasion, flow 
cytometry, in vivo lung metastasis 
assay 
Chang, 2006188 
Neuroblastoma ST8Sia II SH-SY5Y Migration, flow cytometry, Western 
blot 
Al-Saraireh, 2013187
 ST3Gal II, 
ST6Gal I 
B35, CHO Flow cytometry, immunoblotting Preidl, 2014180
a Also ST3Gal II, IV, VI. 
b Normal cell line. 
In vivo evaluation of ST inhibitors in a range of experimental animal xenograft models 
has been reported. These include inhibition of lung metastasis in BALB/c mice induced by 
injection with A549 human lung adenocarcinoma epithelial cells;56 B16F10 human melanoma 
cells;189 murine colon adenocarcinoma 26 sublines of high (NL-17) and low (NL-44) 
metastatic potential;193 or highly metastatic murine 4T1-Luc breast cancer cells.55 A multidrug 
resistant (MDR) leukemia xenograft model in mice injected with K562 (human 
erythromyeloblastoid leukemia) and K562/ADR (adriamycin-resistant) cells has been 
described by Zhang et al.87 In earlier work, a liver metastasis assay was used to assess the role 
of sialyation in hepatic tumour growth in athymic male Swiss nude mice injected with human 
colorectal cells.194 Zebrafish are an emerging live whole animal model for early 
pharmacological assessment of safety and toxicity in drug development,195 and have been 
used for examining the expression and evolution of ST8Sia III196 and its link to neuronal 
migration.197 Mapping of the glycome and glycosyltransferases of zebrafish liver cells 
provides a useful tool for future glycosylation studies in this model system.198 
3. CRYSTALLOGRAPHIC DATA 
As a result of the tremendous therapeutic potential associated with STs, the design and 
development of selective ST inhibitors is a promising new challenge. Efforts have been made 
to identity and understand the structural differences between the different ST subtypes. 
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Accordingly, the crystal structures are obtained with an additive co-crystallized with the 
enzyme, such as CMP (5), CDP (6), the inhibitor CMP-3F-Neu5Ac199 (7) or several different 
sugars, including oligosaccharides. The presence of these compounds provides information 
about the location of the active site. 
Bacteria were found to be a good source for STs. From Campylobacter jejuni, Cst-I was 
isolated and found to promote α-2,3-sialyl patterns200 and Cst-II, which is multifunctional, 
catalyses both α-2,3- and α-2,8-sialylation.201 Crystallization of PM0188, an α-2,6-ST from 
Pasteurella multosida, has been reported by Kim et al.202,203 However, PM0188 presents very 
low sequence homology to other sialyltransferase families. From the same bacteria, 
24PmST1 was also examined. The enzyme shows α-2,3-ST, α-2,6-ST, sialidase and trans-
sialidase acitivity.204,205 Additional mutation provided another enzyme, derived from PM0188, 
with inverted substrate selectivity, i.e. from α-2,3 to α-2,6. The crystal structure of this mutant 
enzyme P7H-M117A, expressed in Pasteurella dagmatis was reported by Schmöelzer et al.206 
Ni and Sugiarto et al. successfully generated a mutant version of 24PmST1 and described 
the crystal structure of the name D141N and M144D, respectively.207 M144D showed 
significantly decreased sialidase activity. In a similar approach, the crystal structure of the 
mutant bifunctional α-2,3-ST and α-2,6-ST 29NST was obtained from the bacterias 
Neisseria meningitides. 16psp26ST is a truncated form of JT-ISH-224, mono-functional β-
galactoside α-2,6-ST, cloned from Photobacterium phosphoreum and its crystal structure was 
reported by Kakuta et al.208 Npp23ST, also a truncated form of JT-ISH-224, was later 
crystalized by Iwatani.209 Huynh later reported the structures of 15Pd2,6ST(N) and 
112Pd2,6ST(N) which also are α-2,6-STs from Photobacterium damselae.210 
The first mammalian ST crystal structure was reported by Rao et al.211 The crystalized 
enzyme is a porcine ST3Gal I variant and presents approximately 85% homology with the 
corresponding human ST. From this data, the authors later proposed a mode of binding for the 
donor CMP-Neu5Ac and the acceptor sugar.212 More recently, both rat213 and human214 
ST6Gal I crystal structures were also reported. The latest human crystal structure reported is 
ST8Sia III (Fig. 4).215  
The crystallographic data provides insight on the mode of action of STs and allows the use of 
computational tools to assist structure-based design of inhibitors. Bacterial and mammalian 
STs crystal structures are summarised in table III. All reported PDB files are available on the 
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Table III. Examples of reported crystallographic data for ST substypes and their corresponding PDB 
file names. 
Table III. Examples of reported crystallographic data for ST substypes and their corresponding PDB file names. 
Enzyme Organism PDB file Reference 
Cst-I Campylobacter jejuni 2P2V,a 2P56 Chiu, 2007199 
Cst-II Campylobacter jejuni 1RO7a;1RO8b Chiu, 2004200 
Cst-II Campylobacter jejuni 2X61,b,h 2X62,b 2X63b Lee, 2011215 
PM0188 Pasteurella multocida 2IY7,a 2IY8,a,c 2C83, 2C84b Kim, 2006201 202 
24PmST1 Pasteurella multocida 2EX0, 2EX1b Ni, 2006204 
24PmST1 Pasteurella multocida 2IHJ,a 2IHK,a 2IHZ,a,c 2ILV,b,c Ni, 2007203 
D141N Pasteurella multocida 2IIB,b 2II6b Ni, 2006 
M144D  Pasteurella multocida 3S44b Sugiarto, 2012206 
P7H-M117A Pasteurella dagmatis 4V2U, 4V38, 4V39, 4V3B,b 4V3Cb Schmöelzer, 2015205 
29NST  Neisseria meningitides 2YK4, 2YK5,b 2YK6,d 2YK7a Lin, 2011216 
JT-ISH-224  Photobacterium phosphoreum 2Z4Tb,c Kakuta, 2008207 
Npp23ST  Photobacterium phosphoreum 2ZWIb Iwatani, 2009208 
15Pd2,6ST(N) Photobacterium damselae 4R83, 4R84a Huynh, 2014209 
112Pd2,6ST(N) Photobacterium damselae 4R9V Huynh, 2014209 
ST3Gal I  Sus scrofa (pig) 2WML, 2WNB,b,e 2WNFe Rao, 2009210 
ST6Gal I  Rattus norvegicus (rat) 4MPS Meng, 2013212 
ST6Gal I  Homo sapiens (human) 4JS1,f 4JS2b Kuhn, 2013213 
ST8Sia III Homo sapiens (human) 5BO6,d 5BO7,g 5BO8, 5BO9a,h Volkers, 2015214 
The crystal structure of the enzyme was obtained co-crystalized with a) CMP-3F-Neu5Ac 7, b) CMP 5, c) 
Sia6SLacNAc d) lactose, e) CDP 6, f) 2-nitrophenyl-Galβ1,3GalNAc, g) Cytidine, and h) CTP. 
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4. SIALYLTRANSFERASE INHIBITORS 
Promising in vivo results endow ST inhibitors with a considerable interest in their therapeutic 
potential, particularly in the area of cancer. A large number of compounds have been 
described to date. They belong to different classes of molecules and scaffolds and recent 
discoveries based on natural products or high throughput screening provide even more 
molecular diversity. Consequently, drawing a structure-activity relationship model is a 
difficult task.  
A. Inhibitors from Nature 
Although natural products were used for thousands of years, their isolation and application 
still play critical roles in modern drug development, especially for antibacterial and 
antitumour agents. Soyasaponin I (8) from soybean is a rigid pentacyclic system with a 
trisaccharide component that showed significant inhibition of ST3Gal in vivo (Ki = 2.1 µM) 
(Fig. 5). Along with good cell permeability, this compound exhibited properties relating to 
invasive/metastatic behaviours of cancer cell lines.228 Soyasaponin I was also found to 
specifically inhibit the expression of α-2,3-linked sialic acids without affecting other glycans 
on murine melanoma cells.189 Various steroidal compounds have been reported to exert 
inhibitory effects on ST3Gal I among them, epiandrosterone succinyl ester, isolated from the 
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parasite Schistosoma japonica and known as a glutathione S-transferase inhibitor,229 had an 
IC50 value of 350 µM.
189 From this example, efforts to provide new ST3Gal I inhibitors based 
on aminoacids esters (IC50 = 480 µM) or phosphate (IC50 = 400 µM) conjugates of 
epiandrosterone were undertaken, however the compounds showed lower potency than the 
parent compound.230 
Another steroidal derivative that has attracted attention is lithocholic acid (9) (Fig. 5). 
This compound has been shown to inhibit ST3Gal I (IC50 = 21 µM). Consequently, a series of 
lithocholic acid derivatives were designed by Chang et al. and their activities evaluated on rat 
ST3Gal,230 wherein, succinic and aspartic acids conjugates gave a similar range of affinity 
with the enzyme. On the other hand, the reduction of the carboxylic acid group to the 
corresponding alcohol significantly decreased activity (IC50 = 351 µM). The same effect was 
observed for its phosphorylated analogue (IC50 > 100 µM). The oxidation of the secondary 
alcohol to a ketone also decreased the activity (IC50 = 139 µM). Nevertheless, the conversion 
of the primary alcohol derivative to the azide counterpart gave way to a series of 1,4-
disubstitued triazoles, conveniently obtained by click chemistry. In general, compounds 
bearing an acidic carboxylic group attached to the side chain generally presented increased 
activity when compared to the analogous alcohol. The most active lithocholic acid derivative, 
the L-Asp compound (10) (Fig. 5), was the object of further biological evaluation. The so-
called Lith-O-Asp derivative was found to inhibit migration and invasion in various cancer 
cell lines and showed inhibitory activity towards human umbilical vein endothelial cells.55 By 
decreasing the sialylation of integrin-β1 and consequently inhibiting the expression of 
phospho-FAK, phosphopaxillin and matrix metalloproteases, Lith-O-Asp suppressed cancer 
cell metastasis. This compound was later the object of further clinical studies which suggest a 
promising potential for metastasis treatment.  
Other lithocholic acid derivatives showed encouraging results from pre-clinical 
experiments. AL-10 (11) (Fig. 5), which is structurally related to Lith-O-Asp, exhibited 
inhibition of ST3Gal I (IC50 = 0.88 µM) and ST6Gal I (IC50 = 1.50 µM) in enzyme 
inhibition assays.56 As observed with Lith-O-Asp, the sialylation of α5, αv and β1 
integrins was repressed. As a result, adhesiveness to fibronectin and laminin was reduced, 
leading to decreased migratory activity of the metastaic cells. The test of the 
antimetastatic effect of AL-10 in vivo revealed a 40% reduction of lung metastasis in 
serum biochemical assays. More recently, further derivatives have been prepared based on 
the encouraging results observed with the Lith-O-amino acid compounds.191 Therefore, 
short peptidic units were attached to the 3-O-position of the steroid moiety. All these 
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compounds were tested against ST3Gal I and some of the most potent were also evaluated 
against ST6Gal I. Most compounds showed moderate activity against the enzymes in the 
low micromolar range (12-16) and inhibited the migation of highly metastatic cancer cell 
lines (MDA-MB-231) (Fig. 5). 
Some examples of lithocholic acid derivatives exhibiting ST inhibition are 
commercially available, such as lithocholic acid (CAS: 434-13-9), lithocholylglycine 
(CAS: 474-74-8) and lithocholyltaurine (CAS: 516-90-5). 
However, the binding site for the lithocholic acid derivative is not clearly defined and 
could possibly be allosteric, these compounds shown to exhibit a wide range of off-target 
activities including inhibition of the nuclear pregnane X receptor,231 antagonism of the 
Eph-ephrin system,232,233 activation of Vitamin D receptor,234 agonism of thee TGR5 
receptor,235 interaction with acetylcholine receptors236 and increased invasiveness by up-
regulating urokinase-type plasminogen activator receptor in colon cancer.237 
Three metabolites isolated from the fungus Stachybotrys cylindrospora have been 
reported as ST inhibitors. Lin et al., evaluated the activity of these spirocyclic drimanes 
(Mer-NF5003F or stachybotrydial (17), and the lactone counterpart (18) towards ST3Gal I, 
ST3Gal III and ST6Gal I using a radiolabelled assay162 as well as some fucosyltransferases 
and galactosyltransferases (Fig. 6).238 All compounds showed affinity against the enzyme in 
the low micromolar range as well as some selectivity for ST6Gal I. These terpenes were also 
shown to exhibit a range of off-target effects including myo-inositol monophosphatase 
inhibition,239 activation of Glu-plasminogen,240 antiviral and antiplasmodial241 as well as 
pancreatic cholesterol esterase inhibition.242 
Marine metabolites currently constitute an attractive source of new bioactive structures in 
medicinal chemistry. The Taiwanese cyanobacteria Lyngbya Majuscula was found to produce 
two fatty amides, isomalyngamide A and A-1 (19), which share a common 4-methoxypyrrol-
2(5H)-one scaffold (Fig. 5). The activity of these compounds was examined by Chang et al. 
against proliferation and migration of metastatic human breast cancer cells (MCF-7 and 
MDA-MB-231).186 The study included ST3Gal I inhibition measurement of the natural 
products and their synthetic analogues using Schmidt’s HPLC-based assay.135  
Isomalyngamides themselves show high inhibitory activity (IC50 = 77.2 µM and 65.7 µM 
respectively) and the synthetic analogues (20) displayed even greater affinity (Fig. 5). Once 
again, the authors suggest that the hypersialylation of β1-integrin may play a key role in 




Figure 5. Sialyltransferase inhibitors from Nature. 
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Several flavonoids exhibiting inhibition of STs have been recently reported by Hidari et 
al.243 The radiolabelled assays,172,173 performed using both rat, human ST6Gal I and rat 
ST3Gal I, revealed potent inhibitory activity for some of these compounds, while 
hydrogenation of the pyranone ring led to loss of the activity. Succesful inhibition was 
obtained with derivatives bearing a 3’,4’,5’-trihydroxyphenyl moiety (21-23) (Fig. 5). The 
authors also suggest that glucosylation at the 6-position of the chromene ring may affect 
specific-linkage inhibition of sialylation. Kinetic properties of these compounds were also 
examined for ST6Gal I and revealed mixed inhibition profiles. Epigallocatechin gallate (24), 
was previously shown to moderately inhibit rat brain ST3Gal I (EC 2.4.99.4), IC50 = 2.7 
µM.244 This compound also inhibits fucosyltransferases in a similar order of potency. 
B. Inhibitors Discovered from High Throughput Screening 
Paulson et al. discovered new small molecules with high ST inhibitory activity using 
high-throughput screening (HTS) of compound libraries.177 The molecules were evaluated 
against porcine ST3Gal I, rat ST3Gal III, human ST6Gal I as well as human FUT6 and human 
FUT7. This study includes mildly to very selective inhibitors (25-26) of ST3Gal III with high 
affinity for the enzyme (IC50 = 1.7 µM) whereas the activity towards the other enzymes 
ST3Gal I, ST6Gal I, FUT6 and FUT7 was negligible (Fig. 6). In addition, this compound was 
found to be competitive with the natural donor substrate site.  
High throughput screening of synthetic combinatorial libraries identified a new 
hexapeptide inhibitor for ST3Gal I.245 Comparison of 114 different peptides (NH2-
X6X5X4X3X2X1) revealed that the terminal tryptophan residue (X1) was optimal, and glycine, 
asparagine and arginine were less active. Tryptophan also appeared to be ideal at the three 
following positions (X2, X3, and X4). The authors determined a Ki value of 8.8 µM for 
hexapeptide NH2-GNWWWW (27), showing the most promising activity (Fig. 6). Kinetic 
studies revealed this peptide to be a noncompetitive inhibitor of ST3Gal I. This compound 
also exhibits inhibitory activity toward ST6GalNAc I and ST6GalNAc III. 
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Figure 6. Sialyltransferase inhibitors discovered by high throughput screening. 
 
Not only organic molecules can afford biological activity, but some polyoxomolybdates 
have also been indentified as antitumour,246-248 antibacterial249 or antiviral agents.250 In order 
to elucidate the mechanism of action of such complexes, Seko et al. explored the inhibitory 
activity and selectivity of molybdate, tungstate and vanadate compounds towards a few 
glycosyltransferases including mutated ST3Gal I and ST3Gal II.251 IC50 values of the 
tungstates for ST3Gal I are potent (0.1-1 nM), ten fold lower than for ST3Gal III, ST6Gal I 
and ST6GalNAc I. The other enzymes evaluated (β4Gal-T1, β3Gn-T2 and FUT3) were 
inhibited only weakly or not at all. The vanadate-type compounds appeared to be more 
specific towards ST subtypes than the tungsten-type derivatives. 
C. Acceptor Analogue Inhibitors 
Since the early modified disaccharides reported by Hashimoto’s group,252 a number of 
different types of acceptor-analogue have been designed. N-acetyl-β-lactosamide has been 
modified at the 6-position of the galactose residue, including deoxy (28), mercapto (29), 
O-THP (30) and dissulfide (31) groups. These compounds afforded modest inhibitory 
activity against rat ST6Gal I (Ki = 0.76 to 4.14 mM) and revealed that the 6’-OH group is not 
essential for substrate binding.253 Okazaki et al. also reported methyl 5a’-carba-β-lactoside 
derivatives (32-34) and tested them against rat ST3Gal I and ST6Gal I.254 The inhibitors 
display some activity in the µM range and up to 1/2.8 selectivity ratio was observed. These 
inhibitors exhibit only modest activity (Fig. 7). To our knowledge, no acceptor-analogue 
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inhibitors were reported recently and the existing compounds have been previousy 
reviewed.142 
 
Figure 7. Sialyltransferase inhibitors based on acceptor analogues. 
D. Cytidine-based Inhibitors 
The structure of CMP-Neu5Ac 4 can be divided into three major fragments: the nucleoside 
fragment, the sialic acid fragment and the phosphodiester linker. 
Cytidine fragment: Over the last decade, several research groups focused on the design 
of donor analogue inhibitors. Prevention of glycosyl transfer is mediated by binding in the 
active site of the enzyme in competition with the natural glycosyl donor CMP-Neu5Ac (4). 
These inhibitors generally contain a cytidine component which was found to be essential for 
binding to the enzyme.255 CMP 5, CDP 6 and CTP were shown to exhibit inhibition (Ki = 16 
to 50 µM against rat liver ST6Gal I, Ki = 10 µM competitive inhibition against ST8Sia II).
188 
Uracil and resorcinol derivatives show reduced affinity for ST6Gals255 while being non-
competitive.256 Adenine derivatives showed very low if any activity against ST3Gal I257 and 
ST6Gal I.256 5-Methylcytosine derivatives showed selectivity for ST8Sia258 and the 5-FU 
analogue, for which inhibitory activity was twice as potent.259 
Substitutions and alterations of the ribose fragment were also explored and revealed some 
differences between the ST subtypes. 2’-O-Methyl-CMP promoted 84% inhibition at 250 µM 
against ST3Gal-III and no inhibition against ST6Gal I (CMP exhibited 67% and 49% 
inhibition respectively at the same concentration).258 This result suggests that the environment 
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in the active site is significantly different from one enzyme subtype to another. In addition, 
this confirms that the empty pocket neighbouring the 2’-hydroxyl group, as observed on the 
pST3Gal I crystal structures (PDB ID: 2WNB), provides an avenue for selective ligands. 2’-
Deoxycytidine was evaluated against human serum ST activity and showed very mild 
inhibition, ranging from 5.9% at 100 µM to 32.5% at 1 mM.256 Ara-CMP and ara-CTP 
exhibited mild competitive inhibition against ST6Gal I (Ki = 1.10 mM and 0.50 mM 
respectively).256 Replacement of the furan ring by a 1,3-dioxolane moiety gave inactive 
compounds (IC50 > 100 µM).
257 In a different approach, Tanaka et al. explored the 
replacement of the entire ribose moiety by a peptidic scaffold.260 The general outcome of 
these studies led to the consideration of cytidine as essential for the activity on ST6Gal I.255 
Most cytidine nucleotides act as competitive ST6Gal inhibitors.256 Other examples bearing a 
5FU moiety exhibit modest activity such as the sialic acid-nucleoside conjugate KI-8110 (35) 
(Fig. 8).261 This compound was preliminarily considered a ST inhibitor by indirect evidence, 
observing diminution of sialylation of the cell surface of treated cells. However, it was later 
found to inhibit CMP-Neu5Ac transport into the Golgi.262 
Linker: An interesting feature in KI-8110 35 is the fact that the compound does not bear 
any group mimicking the native phosphate linker. The phosphate linker between the cytidine 
and sialic acid fragments appears to contribute largely to the binding to the active site of the 
enzyme. A few isosteric replacements for the phosphate group were investigated, including 
phosphoramidate analogues prepared stereoselectively.263 The resulting inhibitors exhibited 
moderate activity in the low micromolar range. Replacement of the native phosphate linker 
by phosphonate esters was also evaluated. When the phosphonate group is directly linked 
to the anomeric centre of the sialic acid fragment, weak inhibition is observed (Ki = 250-
780 µM against rat liver ST6Gal I).137 However moderate to weak activity is observed 
when tethered via an ethylene linker (IC50 = 47-3300 µM against rat ST3Gal I and 340-
4300 µM against rat ST6Gal I).264 By using simplified molecular tools, Lee et al. prepared a 
series of 5’-triazolonucleosides to evaluate their activity on rat liver α-2,3-ST.257 In agreement 
with previous observations, the adenine derivatives failed to prove significant inhibition. 
Among the cytidine based molecules, only compound 36 showed significant activity (IC50 = 
37.5 µM). Interestingly, the presence of a phenyl group seems to be a determinant factor, 
presenting a 2-fold improvement over the cyclopentyl counterpart 37 (44% inhibition at 300 
µM) (Fig 8). In order to increase the hydrophobicity of the compounds and improve their cell 
permeability, Kumar et al. explored CMP-Neu5Ac analogues bearing non-charged linkers 
instead of the phosphate group.265 Three neutral patterns were explored: triazole (38), 
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sulphonamide and amide. Further modifications on the sialyl moiety also included 2-deoxy-
2,3-dehydro-acetylneuraminic acid derivatives or aromatic rings. The inhibitory activity of 
these compounds was evaluated against the bacteria C. jejuni Cst 06, using a HPLC-based 
technique,135 and relatively low inhibition observed (10.7-79.4% at 500 µM). The 5’-triazole 
nucleoside analogs, obtained by click chemistry, appeared to be competitive inhibitors. On the 
other hand, two of the most active compounds (39-40) showed non-competitive inhibition, 
suggesting the nitro group could play a role in the binding with the active site of the enzyme 
(Fig. 8). 
 
Figure 8. Structure of CMP-Neu5Ac derivatives with a modified linker. 
Sugar fragment: The most efficient modifications appear on the sialyl residue. The non-
sialyl framework CMP-quinic acid derivative, for example, displays practically identical Ki 
values (44 µM against rat liver α-2,6-ST) to CMP-Neu5Ac 4 (Ki = 46 µM against rat liver α-
2,6-ST). For this purpose, the use of sialyl mimetics, which do not possess glycosidic bonds, 
are suitable to prevent glycosyl transfer. Corresponding phosphonates (sialic acid mimicked 
by a phosphonate or carboxylate linked via a non-hydrolysable spacer) were less potent 
inhibitors. Phosphoramidates containing amino acid as sialyl mimetics (R-CH(CO2H)NH-
CMP) were also found to possess low inhibition towards ST3Gal and ST6Gal. Based on this 
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knowledge, Schmidt’s group prepared a number of CMP-Neu5Ac analogues including 
cyclohexanone moieties, acetylaminocyclohexane and their hydroxylated derivatives.266  
Inspired by 3-fluorosialic acid as a neuraminidase inhibitor, Burkart et al. prepared CMP-
3F-Neu5Ac (7) via the phosphoramidate route.199 The same compound was also synthesised 
using a chemoenzymatic strategy.216 CMP-3F-Neu5Ac inhibits ST6Gal I with Ki = 5.7 µM 
and became a reference compound for inhibition assays. It was also co-crystalised with various 
ST subtype, enabling identification of the active site (cf section 3). 
In analogy to some inhibitors mimicking the transition-state bearing a bicyclo[3.1.0]hex-
2-ene moiety firstly described by Sun,267 Niwayama et al. developed diacid derivatives.268 
The intention of such compounds undergoes a Meinwald rearrangement and the 
stereospecificity is controlled by the use of pig liver esterase. The study provided four new 
compounds, however assessment of their biological activity has not been reported. 
Click chemistry is an elegant way to obtain libraries of highly functionalized compounds. 
Using this methodology, Hosoguchi et al. reported a library of over 70 donor-based inhibitors 
obtained by click reactions between 5’-azidocytidine and 36 commercially available 
alkynes.180 The library is comprised of CMP-Neu5Ac analogues bearing a functionalized 
triazole group at the 5 or 9-position of the sialyl moiety, respectively, assuming that these 
modifications should not significantly affect the binding of the compounds in the active site of 
the enzyme. The ST inhibition was determined using a MALDI-TOF MS-based HTS towards 
ST3Gal III, ST6Gal I as well as α-1,6-FucT. These molecules display inhibitory profiles 
toward the considered enzyme subtypes, ranging from 15 to 80 %, and even selectivity, 
providing important information about the donor binding sites. The authors suggest that a 
flexible loop in mammalian ST6Gal I might be different from those of ST3Gal III, even if 
both share the same natural donor. The derivatives of the 9-modified library did not show 
significant inhibitory activity, but were recognized as the substrate by the enzymes. 
Compound 41 of the 5-modified library show potent inhibitory activity, whereby the 
compound showed a significant selectivity, with strong non-competitive inhibition of ST3Gal 
III (IC50 = 8.2 µM) over moderate competitive inhibition of ST6Gal I (IC50 = 125 µM) (Fig. 
9). This result clearly demonstrates that the sugar transfer reaction is not disturbed by bulky 
substitutions at the 5- or 9-position. It is also interesting to note that the most active 
compounds in this library bear a steroidal moiety. 
In continuation of previous work initiated by Schmidt’s group,135 extended libraries of 
compounds have been synthesized providing active molecules at the submicromolar level on 
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rST6Gal I. Among them, the first series was obtained by coupling cytidine with 
functionalized α-hydroxyphosphonates, using the phosphoramidite route, activated with 1H-
tetrazole.266 The α-hydroxyphosphonate portion of the molecule bears a substituted benzene 
ring, naphthalene of heterocycle269 and this building block was prepared using an asymmetric 
synthetic pathway to promote optically pure synthon. This study indicates that the 
configuration of the stereogenic centre attached to the phosphonate group has little influence 
on the activity. On the other hand, no relevant conclusion evolves from the electronic 
influence (donating of withdrawing) of the substituents present on the aromatic ring. However, 
compound 42, bearing a 3-phenoxy group, presents a significantly increased affinity with the 
enzyme (Fig. 9). This relevant enhancement of the affinity implies the presence of aromatic 
aminoacids in the active site and the phenoxy group would thus promote an aromatic-aromatic 
interaction with them. Phosphoramidate analogues have been prepared stereoselectively,263 
with the (R) compound found to exhibit competitive inhibitory activity (Ki = 68 ± 24 µM) 
however less potent than their phosphodiester counterpart. 
Building on the potent scaffold 42, fluorescent probes were designed.181 Binding affinity 
of the compounds were evaluated using a fluorescence polarisation assay against rST3Gal II, 
hST6Gal I and bacterial PmST1 and Pd2,6ST(N). The probes were found to exhibit activity in 
the low nanomolar range. A fluorescein based tag was attached to the 3- or 4-position of the 
aromatic ring (43) using an acetamide linker and the corresponding analogues bearing a 
glycine spacer were also prepared (Fig. 14). The use of cell-based assays shed light on the 
permeability of the probe and provided evidence that the compounds reached locations inside 
the cell surrounding the nuclei and possibly to the trans-Golgi network. Other assays assessed 
the inhibition of sialylation in two cell lines, Chinese Hamster Ovary cells and B35 
neuroblastoma cells. The authors suggest that a putative membrane receptor may play a key 
role in the vesicular uptake of the compounds. 
Li et al. reported potent cyclopentane-based CMP-Neu5Ac analogues.270 These transition 
state inhibitors also bear a CMP fragment and an α-hydroxyphosphonate moiety and the sialic 
acid fragment was replaced by a five membered ring. In agreement with other inhibitors 
described above, the non-substituted cyclopentyl counterpart 44 displays weaker activity than 
the corresponding phenyl analogue. The design of more elaborate sugar mimic fragments was 
inspired by the structurally related sialidase inhibitor peramivir, which provided the most 




Figure 9. Sialyltransferase inhibitors bearing a modified sialic acid fragment. 
 
E. Bisubstrate Analogues 
Bisubstrate analogues constitute an interesting rational design approach for enzyme inhibition. 
Considering that the major difference between ST subtypes occurs primarily in the acceptor 
site, two main strategies have been explored for the design of bisubstrate analogues. These 
include a lactose unit tethered to an entirely intact CMP-Neu5Ac, or a CMP-KDN, moiety at 
the 3-axial position of the sialic acid residue.271 Thioethers and alkanedithiols (48) were used 
as a linker to attach both fragments together (Fig. 10). All compounds were tested against rat 
ST3Gal I and ST6Gal I. The Neu5Ac derivatives were consistently more potent than the 




Furthermore, a structure-activity relationship study also evaluated a bisubstrate analogue, 
prepared by Izumi’s group and showed only weak inhibitory activity against recombinant 
rat ST3Gal I (IC50 = 1.3 mM) and ST6Gal I (IC50 = 2.4 mM, 49, Fig. 10).
264 This series 
present two key structural features. The linker was replaced by a phosphonate group which is 
no longer a leaving group and the donor and acceptor fragments are tethered with a 
phosphodiester moiety. The potential of bisubstrate ST inhibitors remains to be realised. 
 
Figure 10. Structures of bisubstrate sialyltransferase inhibitors. 
F. Metabolic Inhibitors 
Paulson’s group created two fluorinated monosaccharide analogues as metabolic ST 
inhibitors.187 The strategy uses a modified bioprecusor of CMP-Neu5Ac to obtain the 
inhibitor inside the cell, synthetised in situ by the locally available enzymatic artillery, as 
previously observed with other glycosyltransferases.272 For this purpose, peracetylated 3-
fluorosialic acids (both separated diastereoisomeres 50 and 51) were able to cross the cell 
membrane and, after ‘deprotection’ by cytosolic esterases, get through salvage pathways to 
provide the potent donor-analogous inhibitor CMP-3Fax-Neu5Ac (7) (Ki = 5.7 µM), first 
described by Burkart199 or the corresponding equatorial counterpart 52 (Fig. 11). The presence 
of a fluorine atom at the 3-position of the sialic acid prevents turnover by inductively 
destabilizing the oxocarbenium ion-like transition state of the catalytic process.273 
Furthermore, the structural similarity of these compounds with the natural donors shuts down 
the de novo synthesis of CMP-Neu5Ac because of feedback loops in these pathways, induced 
by their accumulation. As long as evidence for Golgi localization of CMP-3F-Neu5Ac is not 
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clearly established, the inhibition of sialylation is thus thought to result from substrate 
depletion. 
Although highly effective in vitro, subsequent in vivo studies by Paulson involving 
systemic blockade of sialyation in mice revealed the limitations of using global sialylation 
inhibitors such as P-3Fax-NeuAc in vivo due to renal failure. Given the crucial role of 
sialylation in such a myriad of biological processes and particular the high level of expression 
in liver and kidney tissue, this is not unexpected. However, as stated by the authors, these 
results highlight the importance of developing selective, small molecule ST inhibitors for 
therapeutic purposes, while metabolic inhibitors will still have a crucial role to play as 
biological tools in uncovering more about the role of sialylation in disease progression.274 
 
Figure 11. Hypothetical pathway for the activation  of metabolic sialyltransferase inhibitors. Conditions: 
a) cytosolic esterases, b) salvage pathway. 
In a similar approach, Horstkorte et al. explored the activity of 5-N-acyl-modified sialic 
acids on polysialyltransferases.192 The CHO-mutant 2A10 cells either ST8Sia II or ST8Sia IV 
were fed with 5-N-acyl-D-mannosamines. The results showed that the artificial sialic acid 
precursors bearing longer chains, i.e. propanoyl (53), butanoyl (54) and pentanoyl (55), at the 
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5-position considerably reduced cell surface α-2,8-sialylation (Fig. 11). Real time RP-PCR 
demonstrated that these compounds also affected gene expression. Unnatural sialic residues 
were also found to be incorporated into sialoglycoconjugates. These results suggest the 
formation of the corresponding CMP-Neu5Ac derivatives (56-58) which were prepared and 
tested in a different study275 with consistent findings. 
5. STRUCTURE-BASED DESIGN 
A. Computational Tools and Docking 
Computational tools constitute an attractive avenue for the design of new selective and potent 
inhibitors. The recent characterisation of mammalian ST crystal structures have enabled 
visualisation of the substrate-enzyme interactions highlighted by previous mutational studies. 
As predicted, the donor binding site which is highly conserved between the different subtypes, 
remains consistent while the major variations occur in the acceptor site (Fig. 12A and B). 
Insight from crystal structures, such as rat and human ST6Gal I show many similarities. 
Inhibitions in rat enzymes are thus likely to be translatable into human with acceptable error 
aligning with biological results.  
Using recent crystallographic data, research groups have started optimising new 
inhibitors by structure-based design. Kumar et al. designed non-charged inhibitors and docked 
them in the bacterial Cst-I enzyme (PDB: 2P2V).265 Chen et al. proposed a possible binding 
mode for the steroidal inhibitor Lith-O-Asp (10) in pST3Gal I.55 Preidl et al. evaluated the 
binding site of potent fluorescent probes by docking in the bacterial PmST1 (PDB: 2IHZ) and 
pST3Gal I (2WNB).181 Montgomery et al. explored a range of donor and transition state 
analogues towards the human ST6Gal I crystal structure. Molecular dynamics was performed 
in order to validate the proposed mode of binding. Docking studies also reveal that 
compounds considered as donor/transition state analogues, including 42, may in fact bind to 
the acceptor site (Fig. 12C).276 Sujatha et al. established an homology model for the six 
human ST3Gal I-VI by aligning their sequence with the bacterial enzyme Cst-II.277 Grewal et 
al. later created homology models for the human ST6GalNAc I, ST3Gal III and ST8Sia I 
using the crystal structure of the porcine ST3Gal I as a template and evaluated potential 
binding sites for the natural products curcumin and resveratrol.278 
Docking of the inhibitor 41 described by Hosogushi et al.180 into the pST3Gal I crystal 
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(two histidine and a tyrosine residues) were found to be essential for the catalytic activity. By 
using spin-labelled ligands, Liu et al. used an NMR study to identify the relative placement of the 
donor and acceptor sites.226 These methods constituted good complements or even alternatives 
to X-ray crystallography as most reported crystal structures were bacterial STs and the first 
examples of mammalian STs were described only recently (cf Section 3). 













Sugar mimic Nucleoside  
  Sugar mimic Linker Nucleoside 
ST3Gal   Triazole 
tolerated 
Substitution tolerated at 2’-position 







O >> NH > CH2 
PO(OH)2 > CO2H > OH > H 
O prefered on sugar-based derivative 
PhO > HO(CH2)2O > glycerol > 4-NO2-C6H4-O 
-NHAc > -OH > =O 




5-FU analogues tolerated 
Adenine, Resorcinol not active 
ST8Sia R2 Elongated acyl chain  Substitution tolerated at 2’- and 5-position 
 
Comparing the inhibition data from the most active donor and transition-state analogue ST 
inhibitors, the following SAR picture emerges for this class of inhibitor. The cytidine moiety 
appears to play a key role in the interaction of ST inhibitors with the active site of ST6Gal I.  
Any small change dramatically decreases the affinity. The linker between cytidine and the 
sialic acid analogue is also of a great importance. A phosphate group, which acts as a leaving 
group in the natural donor CMP-Neu5Ac, provides the optimal activity. Many other 
functional groups have been evaluated, including amides, amino acids, sulfamides, triazole, 
phosphoramide, phosphonate or even alkyl groups, however, all of these have afforded 
inhibitors exhibiting lower potency. The presence of a negative charge or an acidic group in 
the inhibitor appears to be favourable by interacting with the catalytic amino acid residues, 
histidine or arginine, in the active site of the enzyme. This is particularly the case at position 
Y, which replaces the carboxyl group of sialic acid. 
The configuration of the carbon atom linking X and Y can be either sp2 or sp3, and in 
several examples this position is a chiral centre. R or E configurations tend to be favoured at 
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this centre, however, this is also dependent on the substituents attached. The left hand part of 
the model represents the sialic acid mimic. The best results obtained to-date have been using 
either a sugar derivative, e.g. pyrane ring, or by replacing the complex highly functionalised 
sialic acid ring by an aromatic ring. The presence of a heteroatom at Z, to mimic the pyranyl 
oxygen atom of the natural donor, is also favourable. An oxygen atom at this position results 
in greater affinity than a nitrogen atom, which is greater than a carbon atom, suggesting a 
possible H-bond interaction with a polar residue in the active site.  
R1 refers to the polyhydroxylated side chain of sialic acid. A phenoxy group at R1 has so 
far provided the greatest affinity, offering easier and cheaper synthetic pathways than a sugar 
related chiral polyol. The various ST crystal structures often reveal the presence of several 
hydrophobic residues in this location of the active site, suggesting that aromatic stacking 
interactions may occur between the phenyl group and a tryptophan or tyrosine residue. The 
selectivity achieved between the different enzyme subtypes in recent reports indicates that 
positions R2 and R3 could be interesting tools in the future for developing new selective 
inhibitors. 
6. COMPOUNDS WITH INDIRECT ACTIVITY ON 
SIALYLTRANSFERASES 
In the T84 colon cancer cell line, the secondary bile acid, deoxycholate (DOC, 59) and the 
phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA, 60) were found to decrease 
expression of ST6Gal I to 30% and 13% of the control respectively, mediated by Ca2+ and 
protein kinase C (Fig. 13).280 Similar results were previously observed while examining the 
influence of sodium butyrate on MUC1 expressing Panc1 pancreatic cancer cell line.281 Gene 
expression was monitored by real time PCR for ST3Gal III, ST3Gal IV, ST3Gal VI as well as 
some glycosyltransferases and β-actin. 
Triptolide (61) is an immunosuppressive and antiinflammatory diterpenoid epoxide 
isolated from the perrenial vine Tripterygium wilfordii (thunder god vine) native to China, 
Japan and Korea (Fig. 13).282,283 The vine has been used in Traditional Chinese Medicine for 
centuries for treating inflammation, in particular rheumatoid arthrisits,  and autoimmune 
diseases. Triptolide, one of the major active constituents of the vine, has been shown to inhibit 
cell proliferation in leukemia, neuroblastoma, pancreatic, ovarian, gastric and lung cancer cell 
lines.284,285 Various modes of action have been ascribed to triptolide including its ability to 
cause apoptosis via inhibition of HSP70286,287 and by blocking TNF-alpha-induced activation of 
NF-kappa B.288 Interestingly, triptolide has also been found to downregulate human GD3 
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synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells.289,290 Triptolide 
has reduced growth and metastasis of tumours in various rodent models including polycystic 
kidney disease,291 neuroblastoma, melanoma, and pancreatic, breast and gastric  cancers, 
including S2-013, one of the most aggressive pancreatic-tumour derived cell lines.292,293 The 
antitumour effect of triptolide was found to be comparable or superior to a range of 
conventional antitumour drugs including Taxol, doxorubicin, and cisplatin, as well as 
retaining activity towards drug-resistance cell lines in cell culture studies.293 In addition to its 
antitumour activity, triptolide 61 has multiple reported functions, including immunosuppresive, 
antiinflammatory, and antifertility activity, and is also emerging as a promising new candidate 
for Alzheimer’s disease based on its ability to inhibit BACE1 in a transgenic mouse model.294 
Accordingly, there are several synthetic studies on triptolide and its analogues sinces its first 
report.295-299 Although its physical properties have limited triptolide’s therapeutic potential, a 
synthetic prodrug analogue, minnelide (62), is showing equal promise including against 
tumour-initiating cells responsible for treatment relapse in pancreatic cancer, with  minnelide 
currently in Phase I clinical trials for pancreatic and advanced gastrointestinal cancers at the 
time of writing (Fig. 13).300-305  
 
Figure 13. Natural product derived and synthetic analogues with indirect inhibitory activity on STs. 
Although there is only one study reporting the ST inhibitory activity of triptolide in 
melanoma, the diverse range of functions of this compound and potent activity towards high 
ST-expressing cancers such as pancreatic and ovarian cancer (see Fig. 4), including their drug-
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resistant cell lines, raise the possibilty that disruption of cell surface sialylation may play a key 
role in this compound’s activity in a wide range of diseases. 
Sialyl Lewisx is an important tumour-associated carbohydrate antigen present on cell 
surface glycoconjugates involved in leukocyte migration and cancer metastasis. 
Radhakrishnan et al. reported the formation of sLex epitope in butyrate-treated human 
pancreatic adenocarcinoma cells expressing MUC1 and core 2 N-
acetylglucosaminyltransferase (C2GnT).281 Butyrate treatment stimulates not only the 
transgene but also a group of endogenous GT genes involved in the synthesis of sLex. 5-Aza-
2-deoxycytidine increases sLex production on MUC1 through induction of ST3Gal VI gene 
by inhibiting its methylation in colon cancer cell lines.306 Similar results were observed in 
ovarian cancer, which led to question the validity of using 5-Aza-dC (63) as a treatment as 
potentially facilitates cancer progression and metastasis.307 In a different fashion, cytarabine 
(64) promotes decreased cell surface sialylation in normal human lung tissue (WI-38 cells)308 
and acute leukemia (HL-60 cells)309 by inhibiting CMP-Neu5Ac synthetase via the active 
metabolite araCMP (Fig. 13). 
Calnexin and Calreticulin are transmembrane chaperones in the endoplasmic reticulum 
involved in folding a number of glycoproteins and regulate their uptake in the Golgi 
apparatus. Calnexin was found to bind to ST8Sia I, the GD3 synthase.310 As GD3 is produced 
by responding to environmental stressors, the inactivation of ST8Sia I contributes to regulate 
many biological processes such as apoptosis. Significant increase in Calnexin and calreticulin 
levels were observed in mice with ST3Gal II transgenes.311 
7. BIOLOGICAL TOOLS TOWARDS IMAGING 
Labelling and tracking have become techniques of increasing importance in modern 
biotechnology which are progressively reinforced by advances in material science.312 This 
method enables visualization in cells and organisms as well as the enrichment of specific 
glycoprotein types for proteomic analysis. In addition to the therapeutic potential of ST 
inhibitors, labelled sialic acid and sialic acid analogues are also being explored for their 
diagnostic and prognostic value in imaging sialylation in disease. There are a host of methods 
for interrogating cell-surface sialylation based either on the affinity of natural sialosides for 
specific lectins, biosynthetic incorporation of unnatural sialic acids into cell surface 
glycoproteins that are subsequently detected with complementary labelled substrates, or direct 
incorporation of a labelled entity such as FITC-Neu5Ac.313 
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A. Metabolic Glycoengineering 
Exploitation of the promiscuous glycosylation biosynthetic machinery has allowed the 
incorporation of a wide range of unnatural sialic acids and their biogenetic precursors (e.g., 
ManNAc, Neu5Ac, and CMP-Neu5Ac analogues) into living cells and animals.314,315 Once 
expressed on the cell surface (which can take from just minutes to hours) the functionalised 
sialic acid (typically bearing a free ketone-, azide-, thiol-, or alkyne-moiety) is subjected to a 
bioorthogonal chemoselective ligation reaction to a labelled counterpart.316 Metabolic 
glycoengineering is a rapidly expanding field that was pioneered by C. Bertozzi from 
Stanford and has been reviewed in detail elsewhere.315 Herein selected recent examples are 
included to illustrate the power of this technique in uncovering more about the integral role of 
sialylation in both disease and normal biological process.  
The azide groups being virtually absent in nature constitutes an excellent building block 
for selectively tagging a biomolecular entity. The ‘clickable’ reagent can be introduced using 
a cell-permeable biogenetic precursor of CMP-Neu5Ac bearing an azido or alkynyl group.317 
Once this building block has entered the cell, it utilises the biosynthetic machinery to provide 
the corresponding sialic acid derivative, allowing the reactive residue to appear as a cell 
surface modified glycan.314,315 This concept efficiently allows the incorporation of a modified 
moiety on the cell surface. In this manner, a wide range of modified ManNAc analogues have 
been biosynthetically incorporated into cell surface glycoproteins, with peracetylation 
significantly enhancing cellular uptake of ManNAc analogues (although it has less of an 
effect on sialic acid analogues).318 In particular, peracetylated N-azidoacetylmannosamine, 
Ac4ManNAz (65, Fig. 14), has proven a versatile substrate for copper-free click chemistry319 
or a Staudinger ligation320 for dynamic in vivo imaging in various animal models including 
drosophila larvae,321 mice,322,323 rat,324 and zebrafish.196,325 For example, Ac4ManNAz has 
been employed for the site-specific labelling of the heavy chain, N-glycosylation site of an 
anti-CA 19-9 antibody and used for in vitro and in vivo targeting of pancreatic cancer cells.326 
Ac4ManNAz has also been used to visualise the dynamic sialylation processes occurring 
during epithelial-mesenchymal transition (EMT) in human keratinocyte HaCaT cells via click 
labelling with fluorophores and affinity tags. In addition, incorporating the commercially 
available pan-sialylation inhibitor P-3Fax-Neu5Ac (50), it was found that inhibition of global 
sialylation promoted EMT.327 
Many modified ManNAc and Neu5Ac analogues are commercially available promoting 
further development of this field. In addition, the corresponding alkynyl sugar derivatives 
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such as Neu5Hex (66) have been applied in an analogous manner to couple with azido-
bearing labels (Fig. 14).328 For example, Homann et al. metabolically incorporated Neu5Hex 
into the cell-surface glycocalyx of a human larynx carcinoma cell line (HEp-2), which was 
then labelled with a fluorescence tag using click chemistry.329 Jiang et al. utilised 
peracetylated N-(4-pentynoyl) mannosamine (Ac4ManNAl), an alkyne-tagged metabolic 
precursor of sialic acid, to monitor the kinetics of glycan biosynthesis. Coupling this with an 
electron-donating picolyl azide and BTTPS, a tris(triazolylmethyl)amine-based Cu(I)-
chelating ligand, accelerated efficiency of the CuAAC reaction 20-38-fold. In mammalian 
cells they reported that it takes 30-45 min for incorporation of ManNAc analogues into cell-
surface glycoconjugates, and were able to detect labelled glycans in zebrafish embryos at the 
two-cell stage (0.75–2 hpf).330 
Photo-cross linking diazirine-modified N-acetylmannosamine (ManNAc) have also been 
incorporated into cell surface glycoconjugates in BJA-B, Daudi, and Jurkat cells.331 Upon 
exposure to UV irradiation, they were covalently cross-linked to sialic acid binding partners 
such as Siglec CD22. The compounds were nontoxic and exhibited minimal growth inhibition 
at the testing concentrations. Expanding on this, dual metabolic labelling of sialylated glycans 
using bifunctional sialic acid analogues containing two distinct chemical reporters at the N-
acyl side chain and C9 positions, such as an azide for click labelling and a diazirine for photo 
cross linking, have been described.332 The bifunctional sialic acid analogues 9AzSiaNAl and 
9AzSiaDAz (67) were metabolically incorporated into cellular glycans in Daudi B 
lymphoblast cells and used for two-colour and FRET imaging (Fig. 14). 
B. Fluorescence Imaging  
Preidl et al.181 developed a series of fluorescent mimetics, e.g. 43 of CMP-Neu5Ac based on 
classical Schmidt type ST transition-state analogue inhibitors 42.266 The polyanionic 
fluorescent compounds were efficiently taken up into cells and translocated to compartments 
surrounding the cell nucleus without the need for transfection agents (Fig. 14). All probes 
examined were found to bind to the four commercially available STs employed in their study, 
rST3Gal II, hST6Gal I, and bacterial STs 24PmST1 from Pasteurella multocida and 
Pd2,6ST(N) from Photobacterium damsela. All exhibited nanomolar ST inhibitory activity in 
a fluorescence polarisation based displacement assay with Ki values in the range of 0.66-0.88 
M against the mammalian STs and 0.08-0.39 M against bacterial STs.181 
Wu et al.313 have recently illustrated the clinical potential for fluorescence guided 
intraoperative tumour detection using FITC-labelled sialic acid (FITC-Neu5Ac) (68), which is 
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taken up by a broad range of tumour cell lines in vitro including Raw 264.7 macrophages, 
human epithelial carcinoma (HeLa), human hepatocellular carcinoma (QGY-7701), human 
primary glioblastoma (U87-MG), H22 hepatocellular carcinoma, murine microglial cells (BV-
2) and the human embryonic kidney 293 cells (normal tissue). The FITC-Neu5Ac is 
metabolically incorporated into glycoproteins via a cellular sialylation pathway and 
transported to the cell surface where it is imaged. Furthermore, intravenous injection of FITC-
SA into ICR mice with subcutaneous tumours revealed preferential uptake by tumours in vivo, 
including high target-to-background fluorescence ratios. Live cell imaging using a CMP-
Neu5Ac analogue carrying a fluorescent reporter group was also described by Suzuki et al. 
The compound was found to be a substrate of a CMP-sialic acid transporter and enabled 
visualisation of specific Golgi vesicles.333 
Non-invasive imaging of intracellular ST activity has been described using 
tetramethylrhodamine isothiocyanate labeled asialofetuin (TRITC-AF) as a ST substrate and 
fluorescein isothiocyanate-labeled 3-aminophenylboronic acid (FITC-APBA), which forms a 
stable chemoselective complex with Neu5Ac at physiological pH. The FITC and TRITC 
donor and acceptor FRET pair is encapsulated in a liposome vesicle for intracellular delivery. 
This method can be used to determine ST activity and cell surface sialylation and evaluate 
correlations with malignancy, as well as assessing activity of ST inhibitors.334 
 




C. Biomarkers and Biosensors 
The over-expression of sialylated epitopes such as sialyl Lewisa (sLea); sialyl Lewisx (sLex); 
sialyl Tn (sTn); disialylated gangliosides GD2 and GD3; monosialylated gangliosides GM1 
and GM2; and polysialic acid (PSA), on the cancer cell surface has been well known for 
decades and forms the basis of many existing serum tumour markers on the market including 
carbohydrate antigen CA 19-9 (sLea) for pancreatic cancer.9 The identification of new highly 
sensitive biomarkers for early detection and monitoring of disease is a rapidly expanding area 
and one where a greater understanding of tumour glycosylation and sialylation has immense 
potential to contribute to the development of new diagnostic methods.48,335,336 In addition to 
these ‘natural’ tumour-associated carbohydrate antigens (TACAs), the xeno-autoantigen 
Neu5Gc (2), acquired predominantly from red meat diets and detected in high levels in human 
cancers, also provides a potential target for immunotherapy.335,337,338 There are also increasing 
reports on the development of ultrasensitive biosensors for detecting specific sialylated 
glycans for cancer diagnosis. These include gold nanoparticle bound Sambucus nigra 
agglutinin (SNA) based sensors that bind specifically to α-2,6-sialylated glycans with 
detection limits of 0.03 pg.mL−1; Prussian blue-based nanocomposite sensors; and boronic 
acid-functionalized peptide-based fluorescent sensors with a high specificity for sLex cell-
surface glycans.339-341 
In a different glycoproteomic approach, CMP[14C]Neu5Ac and ST3Gal II were used in 
an 'exchange sialylation' process to radiolabel and characterise cancer-associated mucin type 
O-glycans, which resulted in the identification of a unique 25-35 kDa sialylated glycoprotein 
in pancreatic tumours.342 
8. CONCLUSIONS 
Our ever-expanding knowledge of the intricate role of sialylation in cancer, 
inflammation, immunology and central nervous system disorders, has highlighted the 
therapeutic potential of this important family of enzymes. Today, an overwhelming number of 
studies have established the merits of inhibiting specific STs such as ST3Gal I and ST6Gal I, 
as a powerful new anti-metastatic strategy, with the potential to be effective on drug-resistant 
tumours. A small number of pan-ST inhibitors are commercially available, however, for ST 
inhibitors to proceed to the clinical stage, it is essential that selective inhibitors for the 
different ST subtypes are developed to specifically target those STs over-expressed in cancers 
and to reduce off-target effects. A wide variety of inhibitors have been developed over the last 
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two decades both by rational design and from natural product and high-throughput screening 
efforts. The recent reports of mammalian crystal structures for porcine ST3Gal I, rat and 
human ST6Gal I and human ST8Sia III, has enabled the use of structure-based design to drive 
ST inhibitors design in the future to improve inhibitor selectivity and pharmacokinetic 
profiles. Increased availability of subtype selective, cell-permeable and synthetically 
accessible, small-molecule ST inhibitors in the future will enable further exploration and 
therapeutic exploitation of the role of sialylation in a range of diseases, in particular metastatic 
cancers. In addition to their potential therapeutic role, sialyltransferase inhibitors and their 
analogues are also being explored as diagnostic tools for disease imaging.  
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ABBREVIATIONS 
CDP = Cytidine diphosphate 
CHO = Chinese Hamster Ovary cells 
CMP = Cytidine monophosphate 
CMP-3F-Neu5Ac = Cytidine-5′-monophospho-N-acetyl-3-fluoroneuraminic acid 
CMP-Neu5Ac = Cytidine-5′-monophospho-N-acetylneuraminic acid 
COX-2 = cyclooxygenase-2 
CTP = Cytidine triphosphate 
EMT = epithelial–mesenchymal transition 
FAK = Focal adhesion kinase-1 
FITC = Fluorescein isothiocyanate 
FP = fluorescence polarization 
FUT3 = Fuc-α-1,3/4-Gal-β-1,4/3-GlcNAc-specific galactoside 3(4)-L-fucosyltransferase 
FUT6 = Fuc-α-1,3-Gal-β-1,4-GlcNAc-specific α-(1,3)-fucosyltransferase 
FUT7 = Fuc-α-1,3-Gal-β-1,4-GlcNAc-specific α-(1,3)-fucosyltransferase 
G6P = glucose-6-phosphate 
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GT = Glycosyltransferase 
GWAS = Genome wide association study 
hST = Human sialyltransferase 
HTS = high-throughput screening 
Lith = Lithocholic acid 
LOS = lipooligosaccharide 
MDR = Multi-Drug Resistance 
MM = multiple myeloma 
MS = mass spectrometry 
MUC1 = mucin 1 
NCAM = Neutral cell adhesion molecule 
Neu5Ac = N-Acetylneuraminic acid (sialic acid) 
Neu5Gc = N-Glycolylneuraminic acid 
PDB = Protein data bank 
pST = Porcine sialyltransferase 
rST = Rat sialyltransferase 
SAR = Structure-Activity Relationship 
ST = Sialyltransferase 
Sia6LacNAc = Sia-α-2,6-Gal-β-1,4-GlcNAc 
sLea = sialyl Lewisa 
SLex = sialyl Lewisx 
SSEA4 = stage-specific embryonic antigen 4 
ST = sialyltransferase 
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